Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG-858
- Development stage
- Phase 2
- Lead developer
- Agenus
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal (inferred From Typical Administration Route For Similar Vaccines; Not Explicitly Stated)
01
Overview
AG-858 is a personalized therapeutic cancer vaccine developed using heat shock protein technology. It is designed to treat chronic myelogenous leukemia (CML), particularly in patients who remain cytogenetically positive after treatment with imatinib (Gleevec). The vaccine consists of autologous heat shock protein-peptide complexes (HSPPC-70) derived from the patient's own tumor cells. These complexes are intended to stimulate the immune system—specifically cytotoxic T lymphocytes—to recognize and attack cancer cells while minimizing side effects commonly associated with conventional therapies. The primary mechanism involves inhibition of HSP70 heat-shock proteins, which play a role in tumor cell survival and immune evasion[1][2][5][7].
- Other names
- autologous HSP-70 protein-peptide complexAG 858AG858AG-858
02
Targets
Hsp70 (70 kDa heat shock protein)
Beyond the preview
Go deeper on AG-858.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG-858.